HC Wainwright Estimates Surrozen’s Q1 Earnings (NASDAQ:SRZN)

Surrozen, Inc. (NASDAQ:SRZN) – Investment analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for Surrozen in a note issued to investors on Tuesday, March 24th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.72) for the quarter, up from their prior forecast of ($1.20). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($0.98) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.70) EPS, FY2027 earnings at ($3.70) EPS, FY2028 earnings at ($3.89) EPS and FY2029 earnings at ($3.97) EPS.

Several other brokerages also recently issued reports on SRZN. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Surrozen in a research note on Tuesday. Finally, Wall Street Zen upgraded Surrozen from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Surrozen Stock Performance

Shares of SRZN opened at $28.90 on Thursday. The firm has a market cap of $247.70 million, a P/E ratio of -0.87 and a beta of 0.53. Surrozen has a twelve month low of $5.90 and a twelve month high of $29.59. The firm’s 50 day moving average price is $24.67 and its two-hundred day moving average price is $19.00.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($7.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by ($6.30). The business had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.66 million. Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%.

Insider Activity at Surrozen

In other news, major shareholder Group Gp Lp Column III purchased 18,052 shares of Surrozen stock in a transaction on Tuesday, January 20th. The stock was purchased at an average price of $19.60 per share, with a total value of $353,819.20. Following the transaction, the insider directly owned 1,016,658 shares in the company, valued at $19,926,496.80. The trade was a 1.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Tcg Crossover Gp Ii, Llc purchased 106,658 shares of the firm’s stock in a transaction dated Tuesday, March 24th. The shares were acquired at an average cost of $24.69 per share, with a total value of $2,633,386.02. Following the completion of the purchase, the insider directly owned 736,554 shares in the company, valued at approximately $18,185,518.26. This represents a 16.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 330,291 shares of company stock worth $7,478,785 in the last 90 days. Company insiders own 45.18% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SRZN. China Universal Asset Management Co. Ltd. increased its stake in Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after buying an additional 500 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Surrozen during the 4th quarter worth about $99,000. Citadel Advisors LLC grew its holdings in shares of Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after acquiring an additional 3,424 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Surrozen in the fourth quarter valued at about $247,000. Finally, Geode Capital Management LLC increased its position in shares of Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares during the last quarter. Institutional investors own 66.57% of the company’s stock.

Key Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buying: TCG Crossover GP II purchased 106,658 shares on March 24 (~$2.63M at ~$24.69) as part of a recent string of purchases, materially increasing its stake and signaling insider conviction that can support the stock. InsiderTrades: Major Shareholder Purchases
• Positive Sentiment: Follow-on insider buy: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90 (SEC filing disclosed), reinforcing the same insider-buy signal. American Banking News: Tcg Crossover Acquires Shares
• Positive Sentiment: Analyst support: Cantor Fitzgerald gave an “Overweight” rating and a $40 target, and HC Wainwright reiterated a “Buy” and raised targets/longer-term EPS forecasts — both items tend to attract buyer interest and can lift sentiment. American Banking News: Cantor Fitzgerald Rating American Banking News: HC Wainwright Buy Rating
• Positive Sentiment: HC Wainwright commentary on FY2030 shows a materially less-negative multi-year EPS path in their model (raises to FY2026–FY2029/FY2030 estimates), suggesting improving operating/profitability assumptions versus consensus. American Banking News: HC Wainwright FY2030 Comments
• Neutral Sentiment: Short-interest / days-to-cover data in some reports appears inconsistent (some sources show zero shorts / NaN), so treat short-interest as unreliable in explaining the move today.
• Negative Sentiment: Lifesci Capital cut near-term EPS estimates across Q1–Q4 2026 and trimmed FY2026, signaling more conservative short-term cash/burn or program timing assumptions — a reminder of execution and cash-risk that could cap upside. MarketBeat: Analyst Estimate Changes

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.